Core Insights - Stevanato Group reported solid financial results for Q4 and fiscal 2025, with significant growth in its Biopharmaceutical and Diagnostic Solutions (BDS) segment and high-value products related to GLP-1 therapies driving revenue and margin expansion [4][3][7] Financial Performance - Q4 total revenue increased by 7% at constant currency to EUR 346.5 million, with BDS revenue up 13% and engineering revenue down 23% [2] - For fiscal 2025, total revenue rose 9% at constant currency, with High-Value Solutions growing 29% and contributing to a 160 basis points gross margin expansion [3][7] - Adjusted EBITDA for Q4 was EUR 97.7 million, with an adjusted EBITDA margin of 28.2% [7] Segment Performance - BDS segment showed double-digit growth, while engineering faced a decline due to lower order intake [3][21] - High-Value Solutions accounted for approximately 49% of total revenue in Q4 and 46% for the fiscal year [2][3] GLP-1 Exposure - GLP-1-related sales represented about 19-20% of total revenue in 2025, growing over 50% year-over-year, with expectations for mid-teens growth in 2026 [6][8] - The Nexa syringe was highlighted as the fastest-growing product, but capacity constraints are anticipated to persist into 2026 [8][10] Capacity and Investment - The company is ramping up capacity in its Latina and Fishers facilities, with significant investments planned for 2026 to meet rising demand [13][14] - CapEx for 2026 is projected between EUR 270 million to EUR 290 million, with a focus on growth projects [22] Guidance for 2026 - Stevanato expects revenue of EUR 1.26–1.29 billion and adjusted EBITDA of EUR 331.8–346.9 million for 2026, with a forecasted tax rate of approximately 26.8% [5][27] - The company anticipates stronger revenue in the second half of 2026 compared to the first half, with BDS growth expected to be in the high single- to low double-digits [21][22] Operational Improvements - The engineering segment has seen operational enhancements, but revenue is expected to decline in 2026 due to slower order conversion [16][17] - Management noted that site acceptance rates have improved significantly, indicating better execution in engineering projects [16]

Financial Data and Key Metrics Changes - For fiscal 2025, total company revenue increased by 9% at constant currency rates and 7% on a reported basis compared to 2024, reaching EUR 1.26 billion to EUR 1.29 billion for 2026 guidance [5][23] - Gross profit margin rose by 160 basis points compared to 2024, driven by strong performance in High-Value Solutions [6] - For the fourth quarter of 2025, total company revenue grew 7% at constant currency and 5% on a reported basis to EUR 346.5 million [16] Business Line Data and Key Metrics Changes - The Biopharmaceutical and Diagnostic Solutions (BDS) segment delivered double-digit growth, with revenue increasing 13% at constant currency and 10% on a reported basis for Q4 2025 [16][19] - Revenue from High-Value Solutions grew 31% to EUR 171 million in Q4 2025, representing approximately 49% of total company revenue for the quarter [17] - The engineering segment experienced a 23% revenue decline in Q4 2025, attributed to lower revenue in glass conversion and assembly [20] Market Data and Key Metrics Changes - Revenue from GLP-1s accounted for approximately 19%-20% of total company revenue in 2025, growing more than 50% compared to 2024 [8] - The company expects GLP-1s to serve as a meaningful tailwind as patient demand continues to grow, with a projected mid-teens growth rate for 2026 [29][30] - Biologics represented 41% of BDS revenues in 2025, up from 34% in 2024, indicating a growing market presence [10] Company Strategy and Development Direction - The company is focused on high-value solutions and has invested in expanding capacity for high-value syringes in Fishers, Indiana, and Latina, Italy [7] - The strategy includes pivoting away from non-high-value product categories and increasing participation in the broader set of biologic applications [10][15] - The company aims to align growth investments with customer demand trends and capitalize on opportunities in the evolving market [15][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the robust demand for biologics and the company's ability to meet this demand through its integrated value proposition and innovative products [25] - The company anticipates that the engineering segment will take longer to regain momentum due to a slower-than-expected sales cycle [32] - Management highlighted the importance of operational progress and the expectation of benefiting from new capacity and productivity gains in the future [26][25] Other Important Information - The company ended fiscal 2025 with cash and cash equivalents of EUR 130.6 million and net debt of EUR 337.7 million, indicating a solid liquidity position [21] - Capital expenditures for 2025 totaled EUR 294.9 million, with approximately 89% allocated for growth projects [21] Q&A Session Summary Question: Expectations for GLP-1 growth in 2026 - Management expects GLP-1 revenue growth in the mid-teens for 2026, following a 50% growth in 2025 [29] Question: Insights on engineering segment order intake - Management noted that the sales cycle for engineering projects is longer than anticipated, but the order pipeline remains healthy [31] Question: Capacity constraints for High-Value Solutions - Management confirmed that capacity constraints were experienced in 2025, but robust demand is expected to continue into 2026 [37] Question: Long-term growth outlook for GLP-1s - Management believes GLP-1s will continue to be a significant growth driver, with a strong demand forecast for the next decade [46][80] Question: Performance of non-GLP biologics - Management indicated that non-GLP biologics are expected to grow, with a focus on high-value products and increasing customer engagement [68]

Financial Data and Key Metrics Changes - For fiscal 2025, total company revenue increased by 9% at constant currency rates and 7% on a reported basis compared to 2024, reflecting the execution of strategic priorities [4][5] - In the fourth quarter of 2025, total company revenue grew 7% at constant currency and 5% on a reported basis to EUR 346.5 million [15] - Gross profit margin for the fourth quarter increased by 120 basis points to 30.9%, driven by a favorable mix of high-value solutions and operational improvements [16][18] - Net profit for the fourth quarter totaled EUR 47.6 million, with diluted earnings per share at EUR 0.17 [17] Business Line Data and Key Metrics Changes - The Biopharmaceutical and Diagnostic Solutions (BDS) segment delivered double-digit growth in fiscal 2025, with revenue increasing 13% at constant currency and 10% on a reported basis [15][19] - Revenue from high-value solutions in the BDS segment grew 31% to EUR 171 million in the fourth quarter, representing approximately 49% of total company revenue for the quarter [16][18] - The engineering segment experienced a 23% revenue decline in the fourth quarter due to lower revenue in glass conversion and assembly [19] Market Data and Key Metrics Changes - Revenue from GLP-1s accounted for approximately 19%-20% of total company revenue in 2025, growing more than 50% compared to 2024 [7][29] - The company expects GLP-1s to serve as a meaningful tailwind as patient demand continues to grow [7][8] - Biologics represented 41% of BDS revenues in fiscal 2025, up from 34% in 2024 [9] Company Strategy and Development Direction - The company is committed to meeting customer demand for high-value solutions, investing in key projects to expand capacity for high-value syringes [6][10] - The strategy includes pivoting away from non-high-value product categories and focusing on premium products [5][14] - The company aims to align growth investments with customer demand trends and capitalize on opportunities in the biologics market [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the robust demand for biologics and the company's ability to capitalize on this through its integrated value proposition [24] - The company anticipates that the engineering segment will face challenges in the near term but expects to regain momentum with a strong opportunity pipeline [12][32] - Management highlighted the importance of operational progress and the expected benefits from new capacity coming online [25][41] Other Important Information - The company ended the year with cash and cash equivalents of EUR 130.6 million and net debt of EUR 337.7 million, indicating sufficient liquidity to fund strategic priorities [20] - Capital expenditures for 2025 totaled EUR 294.9 million, with approximately 89% allocated for growth projects [20][21] - The company expects revenue for 2026 to range between EUR 1.26 billion and EUR 1.29 billion, with adjusted EBITDA projected between EUR 331.8 million and EUR 346.9 million [22][23] Q&A Session Summary Question: Expectations for GLP-1s in 2026 - Management expects GLP-1 revenue growth in the mid-teens for 2026, following a 50% growth in 2025 [29][30] Question: Insights on Engineering Segment Order Intake - Management noted that the sales cycle for engineering projects is longer than anticipated, impacting order intake, but the pipeline remains healthy [31][32] Question: Capacity Utilization for High-Value Solutions - The company is currently operating at full capacity for high-value solutions and is ramping up production in Latina and Fishers [37][38] Question: Margin Expansion Drivers - Management indicated that margin expansion will be driven by a favorable project mix and operational improvements, despite headwinds from depreciation and currency effects [41][42] Question: Long-term Growth Outlook for GLP-1s - Management believes GLP-1s will continue to be a significant growth driver, with a strong demand outlook for biologics [82][83]